590 results on '"Mathijssen, Ron H.J."'
Search Results
102. Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
103. Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
104. Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
105. Development and validation of an UPLC–MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair
106. A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures
107. Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
108. Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer
109. Adding metabolic agents to prostate cancer therapy
110. Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
111. Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
112. The influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosis
113. Influence of darolutamide on cabazitaxel systemic exposure.
114. Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
115. Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types
116. PET-CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients
117. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine:Results of A Randomized Crossover Trial
118. Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas
119. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma:a phase I/II dose escalation and safety study-INTERACT MESO
120. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil:A Note of Caution Based on a Large Prospective Clinical Study
121. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer:results from the prospective TOTAM trial
122. Tamoxifen use and potential effects on liver parenchyma:A long-term prospective transient elastographic evaluation
123. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
124. Influence of esomeprazole on the bioavailability of afatinib:A pharmacokinetic cross-over study in patients with non-small cell lung cancer
125. CABA-V7:a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients
126. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing:Feasible in Patients with Hormone-Sensitive Breast Cancer
127. Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
128. Hyperhydration with cisplatin does not influence pemetrexed exposure
129. Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer:A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
130. Nivolumab for Squamous-Cell Cancer of Head and Neck
131. Is uracil enough for effective pre-emptive DPD testing?
132. Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding
133. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
134. Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer: Adding enzalutamide to cabazitaxel in hormone refractory PCa
135. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
136. Drug transporters of platinum-based anticancer agents and their clinical significance
137. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
138. Precision Dosing of Targeted Therapies Is Ready for Prime Time
139. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy
140. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
141. Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation
142. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
143. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
144. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
145. Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
146. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
147. Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
148. Germline variation in pdcd1 is associated with overall survival in patients with metastatic melanoma treated with anti‐pd‐1 monotherapy
149. The added value of H2 antagonists in premedication regimens during paclitaxel treatment
150. CYP3A4∗22 Genotyping in Clinical Practice:Ready for Implementation?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.